基于FDA不良事件报告系统数据库对 cetuximab 的ADR 报告的分析
Shuai Zhao1, Yan Wang2, Xiaoli Deng3
1Department of Galactophore, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
Scientific reports
|February 3, 2025
概括
这项研究使用FDA数据监测了 cetuximab 的不良事件 (AE),识别了新的安全信号,如语音障碍和传播的血管内凝血,以改善患者的护理.
科学领域:
- 药物监督 药物监督 药物监督
- 瘤学 药物安全 药物安全
- 监管科学 监管科学
背景情况:
- 塞图西马布是转移性癌症的关键疗法.
- 监测不良事件 (AE) 对于患者的安全至关重要.
- 识别未标记的副作用可以改善临床指导.
研究的目的:
- 通过使用FDA FAERS数据,回顾性地分析 cetuximab 相关的副作用.
- 通过不成比例分析来识别和量化重要的AE信号.
- 检测未在 cetuximab 标签上列出的新药不良反应 (ADR).
主要方法:
- 对FDA FAERS数据库 (2013 Q12022 Q4) 的回顾性分析.
- 不成比例的分析:ROR,PRR,BCPNN,EBGM算法. 没有一个.
- 在系统器官类 (SOC) 中识别显著的首选术语 (PT).
主要成果:
- 分析了5,186份主要疑似 cetuximab AE 报告.
- 在22个SOC中确定了176个重要的PT.
- 关键的SOC:皮肤/皮下组织,研究,新陈代谢,血液/淋巴系统疾病 (58.63%).
- 检测到未标记的AE:语言障碍,椎间盘膜炎,快速进展的淋巴结膜炎,DIC.
结论:
- 塞图西马布的使用与许多副作用有关,包括新的信号.
- 持续的药物监测对于检测和管理 cetuximab 的副作用至关重要.
- 这些发现提高了对 cetuximab 安全性概况的理解,有助于临床决策.
相关概念视频
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...